BLOOMBERG BNA WEBINAR EVENT: The Road Forward: Hatch-Waxman Litigation Settlements in the Wake of FTC v. Actavis
Thursday, October 10, 2013
3:00 PM - 4:30 PM ET
Recently, the U.S. Supreme Court handed down a precedential decision – Federal Trade Commission v. Actavis, Inc. – regarding the legality of reverse settlement payments that arise from Hatch-Waxman based patent litigations. This decision will impact future settlements and their treatment by the FTC. The faculty will provide an overview of the issue and the Supreme Court holding, followed by a more detailed analysis of its impact on the pharmaceutical industry.
Attendees will walk away with a heightened understanding of the impact this case has on pharmaceutical litigation settlements, including tips on how these settlements can be structured to reduce FTC scrutiny.
- Thoroughly understand reverse settlement payments.
- Learn about the holding in FTC v. Actavis.
- Find out how this decision will impact future pharmaceutical litigation.
- Discover how to better negotiate and structure future settlements.
Who would most benefit from attending this program?
Outside Counsel, in-house counsel, business decision makers and related intellectual property professionals.
Program Level: Intermediate.
Credit Available: This program’s CLE-credit eligibility varies by state.